IRulya Therapeutics, Inc. (IRLA)
32.95
+1.33
(+4.21%)
USD |
NASDAQ |
Oct 30, 16:00
33.50
+0.55
(+1.67%)
After-Hours: 20:00
IRulya Therapeutics Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.0259 |
| December 31, 2025 | -0.5172 |
| September 30, 2025 | 16.99 |
| June 30, 2025 | 1.490 |
| March 31, 2025 | 0.8477 |
| December 31, 2024 | 0.4913 |
| September 30, 2024 | 0.3439 |
| June 30, 2024 | 0.3062 |
| March 31, 2024 | 0.19 |
| December 31, 2023 | 0.1624 |
| September 30, 2023 | 0.0007 |
| June 30, 2023 | 0.0017 |
| March 31, 2023 | 0.003 |
| December 31, 2022 | 0.0045 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.004 |
| June 30, 2022 | 0.0047 |
| March 31, 2022 | 0.0032 |
| December 31, 2021 | 0.0098 |
| September 30, 2021 | 0.0102 |
| June 30, 2021 | 0.0104 |
| March 31, 2021 | 0.0024 |
| December 31, 2020 | 0.0026 |
| September 30, 2020 | 0.0028 |
| June 30, 2020 | 0.0012 |
| March 31, 2020 | 0.0005 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.0123 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Korsana Biosciences, Inc. | 0.00 |
| PepGen Inc. | 0.1346 |
| Q32 Bio, Inc. | 0.05 |
| Bridgebio Oncology Therapeutics, Inc. | 0.0078 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 124.00M |
| Total Liabilities (Quarterly) | 15.51M |
| Shareholders Equity (Quarterly) | 108.49M |
| Current Ratio | 14.52 |
| Net Debt Paydown Yield | 17.03% |